CHF, Chronic Heart Disease, Congestive Heart Failure, Heart Failure
Conditions
Keywords
Cardiac Contractility Modulation, CCM, FIX-HF-5CA, Continued Access
Brief summary
This is a multicenter, prospective, single-arm Continued Access study of the Optimizer Smart System with CCM therapy.
Detailed description
The Continued Access study is a prospective, non-randomized, multi-center study designed to allow controlled access to the Optimizer Smart System until the PMA order has been issued by the FDA.
Interventions
DEVICEOptimizer Smart System
The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
Sponsors
Impulse Dynamics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Continued Access
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects who are 18 years of age or older 2. Subjects who have a baseline ejection fraction greater than or equal to 25% and less than or equal to 45% by echocardiography. 3. Subjects who, in the opinion of the Investigator (based on the current guidelines for clinical practice), have been treated for heart failure for at least 90 days and are currently receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure. 4. Subjects who are in New York Heart Association functional Class III and IV at the time of enrollment. 5. Subjects who are willing and able to return for all follow-up visits.
Exclusion criteria
1. Subjects who have a potentially correctible cause of heart failure, such as valvular heart disease or congenital heart disease. 2. Subjects receiving any form of inotropic support within 30 days before enrollment, including subjects on continuous IV inotrope therapy. 3. Subjects hospitalized for decompensated heart failure requiring acute treatment with intravenous loop diuretics, IV inotropes or hemofiltration within 30 days before enrollment and baseline testing. 4. Subjects who have a clinically significant amount of ambient ectopy, defined as more than 8,900 PVCs per 24 hours on baseline Holter monitoring. 5. Subjects having a PR interval greater than 375ms. 6. Subjects who are scheduled for a CABG or a PTCA procedure, or who have undergone a CABG procedure within 90 days or a PTCA procedure within 30 days of enrollment. 7. Subjects who have a biventricular pacing system, an accepted indication for such a device, or a QRS width of 130ms or greater. 8. Subjects who have had a myocardial infarction within 90 days of enrollment. 9. Subjects who have mechanical tricuspid valve. 10. Subjects who have a Left Ventricular Assist Device or prior heart transplant. 11. Subjects on dialysis. 12. Subjects who are participating in another experimental protocol. 13. Subjects who are unable to provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Observed Mortality Comparison to the Predicted Probability of Mortality | 2 years 6 months | The FIX-HF-5CA Study was unofficially intended to serve as the Post-Approval Study (PAS) with the intention of collecting 3 year observed mortality data and comparing that to the predicted probability of mortality derived from two validated heart failure models \[MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) and SHFM (Seattle Heart Failure Model)\]. The objective was to show that the observed prevalence of mortality was not worse than the derived predicted probability of mortality. Upon PMA and PMA Supplement approval of the device, however, FDA and the Sponsor stopped this 5CA study and a new PAS was initiated (NCT03970343). No long-term mortality data or final analysis was collected for this study. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Optimizer Smart System (3-Lead) All eligible subjects will have the Optimizer Smart System 3-Lead implanted and receive cardiac contractility modulation therapy (CCM).
Optimizer Smart System: The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day. | 70 |
| Optimizer Smart System (2-Lead) All eligible subjects will have the Optimizer Smart System 2-Lead implanted and receive cardiac contractility modulation therapy (CCM).
Optimizer Smart System: The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day. | 36 |
| Total | 106 |
Baseline characteristics
| Characteristic | Optimizer Smart System (3-Lead) | Total | Optimizer Smart System (2-Lead) |
|---|---|---|---|
| Age, Continuous | 65 years | 66 years | 66 years |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 9 Participants | 14 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) White | 59 Participants | 89 Participants | 30 Participants |
| Region of Enrollment United States | 70 Participants | 106 Participants | 36 Participants |
| Sex: Female, Male Female | 26 Participants | 36 Participants | 10 Participants |
| Sex: Female, Male Male | 44 Participants | 70 Participants | 26 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 5 / 70 | 0 / 36 |
| other Total, other adverse events | 12 / 70 | 3 / 36 |
| serious Total, serious adverse events | 13 / 70 | 4 / 36 |
Outcome results
Primary
Observed Mortality Comparison to the Predicted Probability of Mortality
The FIX-HF-5CA Study was unofficially intended to serve as the Post-Approval Study (PAS) with the intention of collecting 3 year observed mortality data and comparing that to the predicted probability of mortality derived from two validated heart failure models \[MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) and SHFM (Seattle Heart Failure Model)\]. The objective was to show that the observed prevalence of mortality was not worse than the derived predicted probability of mortality. Upon PMA and PMA Supplement approval of the device, however, FDA and the Sponsor stopped this 5CA study and a new PAS was initiated (NCT03970343). No long-term mortality data or final analysis was collected for this study.
Time frame: 2 years 6 months
Population: All subjects implanted with the Optimizer System.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Optimizer Smart System (3-Lead) | Observed Mortality Comparison to the Predicted Probability of Mortality | 5 Participants |
| Optimizer Smart System (2-Lead) | Observed Mortality Comparison to the Predicted Probability of Mortality | 0 Participants |